We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
- Authors
Seropian, S; Bahceci, E; Cooper, D L
- Abstract
Summary:A high incidence of nonrelapse mortality (NRM) has limited the use of allogeneic transplantation for poor prognosis non-Hodgkin's lymphoma (NHL). We sought to improve the outcome of allografting by utilizing Filgrastim-mobilized peripheral blood stem cells (PBSC) in combination with either standard ablative or reduced-intensity conditioning. A total of 21 patients with intermediate/high-grade lymphoma and seven patients with low-grade histology were enrolled on protocols using PBSC. All patients were considered high risk for recurrence and/or NRM because of age >50 (n=16), refractory disease (n=17), failed autologous transplant (n=11) and abnormal organ function (n=2). In all, 17 patients received ablative regimens and 11 received modified conditioning including fludarabine, intravenous busulfan and ATG. Tacrolimus and mini-dose methotrexate were used for graft-versus-host-disease (GVHD) prophylaxis. Median follow-up was 38 months. Disease-free and overall survival were 57 and 58%. Seven of the 11 patients who relapsed after a previous transplant remain disease free. Four of the 10 patients with recurrent/persistent disease post transplant responded to additional therapy including withdrawal of immunosuppression±DLI. These results support a potent graft-versus-lymphoma effect and suggest that patients who relapse after an autologous transplant can be salvaged with an allogeneic transplant.Bone Marrow Transplantation (2003) 32, 763-769. doi:10.1038/sj.bmt.1704233
- Subjects
STEM cells; CELL transplantation; TRANSPLANTATION of organs, tissues, etc.; LYMPHOMAS; MORTALITY
- Publication
Bone Marrow Transplantation, 2003, Vol 32, Issue 8, p763
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/sj.bmt.1704233